Phase III randomized, controlled, open-label trial to investigate the antiviral activity, tolerability and safety of TMC114/r in treatment-naive HIV-1 infected patients.

Trial Profile

Phase III randomized, controlled, open-label trial to investigate the antiviral activity, tolerability and safety of TMC114/r in treatment-naive HIV-1 infected patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Darunavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ARTEMIS
  • Most Recent Events

    • 16 Feb 2017 Results (n=2329) of seven phase 2 and 3 studies (ARTEMIS, GS-US-299-0102, ODIN, MONET,PROTEA, GS-US-216-0130,INROADS ) presented at the 24th Conference on Retroviruses and Opportunistic Infections.
    • 23 Oct 2012 Primary endpoint 'Virological-response-rate' has been met.
    • 29 May 2012 Actual end date May 2012 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top